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Abstract
Background: The use of quinolone prophylaxis in high-risk neutropenic patients is considered standard of care but
the development of resistance is a concern. Previous studies have focused mainly on quinolone resistance among
patients receiving prophylaxis, with very few data reporting its impact on the hospital microbial epidemiology.
Methods: We analyzed a cohort of 329 episodes of chemotherapy-induced neutropenia in adults, and compared
two periods: 2005 (period 1, no prophylaxis, n=110) and 2006-2008 (period 2, ciprofloxacin prophylaxis, n=219).
Outcomes analyzed were the frequency of febrile neutropenia, bacteremia, duration of antibiotic therapy and
hospitalization, and antimicrobial resistance to ciprofloxacin and extended-spectrum beta-lactamase [ESBL]
production. We analyzed resistance rates (by patients-day) in the cohort, as well as in other patients (neutropenic
and non-neutropenic, 11,975 patients-day) admitted to the hematology unit in the same period, taking into
consideration the general resistance patterns in the hospital.
Results: Quinolone prophylaxis (period 2) resulted in fewer episodes of febrile neutropenia (159/219 [73%]
vs. 102/110 [93%], Chi-square 18.09, p = 0.00002), and bacteremia (49/219 [22] vs. 36/110 [33%], Chi-square 4.10,
p = 0.04), shorter duration of antibiotic therapy (p = 0.0002) and hospitalization (p = 0.002), but more frequent
use of carbapenems (79/219 [36%] vs. 15/110 [14%], Chi-square 18.06, p = 0.0002). In addition, period 2 was
associated with higher rates of quinolone resistance (6.77 vs. 3.02 per 1,000 patients-day, p = 0.03). The rate
of ESBL-producing enterobacteria in the two periods was slightly higher in patients receiving quinolone
prophylaxis (1.27 vs. 0.38 per 1,000 patients-day, p = 0.26) as well as in the hematology unit overall (1.59 vs. 0.53
per 1,000 patients-day, p = 0.08), but remained stable in the whole hospital (0.53 vs. 0.56 per 1,000 patients-day,
p = 0.74).
Conclusions: Ciprofloxacin prophylaxis was beneficial in high risk neutropenic patients, but important
modifications in the prescription of carbapenems and on antimicrobial resistance patterns of isolates were
observed. The importance of hospital or ward ecology must be taken into account when deciding for
quinolone prophylaxis in high-risk neutropenic patients.
Keywords: Neutropenia, Prophylaxis, Quinolone, Febrile neutropenia, Resistance
* Correspondence: mnucci@hucff.ufrj.br
1Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio
de Janeiro, Rua Professor Rodolpho Paulo Rocco 255, Cidade Universitária,
Rio de Janeiro 21941-913, Brazil
Full list of author information is available at the end of the article
© 2013 Garnica et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Garnica et al. BMC Infectious Diseases 2013, 13:356
http://www.biomedcentral.com/1471-2334/13/356
Background
The use of quinolone prophylaxis in neutropenic cancer
patients has been associated with a reduction in the inci-
dence of bacterial infections and mortality [1-4]. How-
ever, an increase in quinolone resistance [5-7], as well as
resistance to other classes of antimicrobial agents, such
as extended-spectrum beta-lactamase (ESBL) production
among enterobacteria has been reported [8-12]. The po-
tential increase in resistance with the use of quinolones
is relevant in the neutropenic setting, because the high
incidence of infection caused by ESBL-producing bac-
teria limits the options for empirical treatment of febrile
neutropenia. Furthermore, in a setting of a high preva-
lence of Gram-negative resistance, the use of inappropri-
ate antibiotic therapy results in significant excess mortality
[13]. Studies reporting antimicrobial resistance among
neutropenic patients receiving quinolone prophylaxis have
focused mostly on the emergence of quinolone resistance
among patients receiving prophylaxis, with very few data
reporting its impact on the hospital microbial epidemi-
ology [5,14].
In Brazil the rates of Gram-negative bacteremia in
neutropenic patients are high [15], rendering quinolone
prophylaxis an attractive approach. However, the rates
of resistance among Gram-negative bacilli are high in
the region [16]. Therefore, an analysis of the potential
benefits of quinolone prophylaxis must be carefully
weighed against the risks of resistance. In the present
study we evaluated the impact of quinolone prophylaxis
given during neutropenia on different outcomes, with
special attention to the rates of resistance among patients
on prophylaxis, as well as in patients admitted to the
hematology unit in the same period, taking into consid-
eration the general resistance patterns in the hospital.
Methods
We conducted an observational study at Hospital Uni-
versitário Clementino Fraga Filho, Federal University of
Rio de Janeiro, Brazil. This is a tertiary care hospital
with ~400 beds, including a hematology and hemato-
poietic cell transplant (HCT) unit with 8 single-bed rooms
with high efficiency particulate air (HEPA) filter and
positive pressure, and five double-bed rooms without
HEPA filter. The study was approved by the institution’s
Ethical Committee (“Comitê de Ética em Pesquisa do
Hospital Universitário Clementino Fraga Filho”).
Until 2006, no antibacterial prophylaxis had been given
to neutropenic patients. Since then, all patients with
hematological malignancies with an expected duration
of neutropenia >7 days received prophylaxis with cipro-
floxacin (500 mg orally twice a day, switched to 200 mg
intravenously twice a day if the patient developed severe
mucositis or intolerance to the oral formulation). Pro-
phylaxis was started concomitantly with the induction
chemotherapy or the conditioning regimen (HCT), and
was maintained until bone marrow recovery or fever.
In case of fever, blood cultures were obtained, and the
patients were immediately started on intravenous cefe-
pime, unless a previous episode of febrile neutropenia
documented a cefepime-resistant Gram-negative organism.
In this case, a carbapenem (imipenem or meropenem)
was started. Blood cultures were repeated in case of
persistent or recurrent fever, or as clinically indicated.
Modifications in the empirical antibiotic regimen were
performed according to the results of cultures and the
clinical course of the patient.
For the purpose of this analysis, we selected all pa-
tients admitted between 2005 and 2008 who fulfilled
the following criteria: a) receipt of chemotherapy with
expected duration of neutropenia >7 days; and b) no
fever or documentation of infection on the first day of
chemotherapy. We then compared patients who received
prophylaxis with ciprofloxacin (2006–2008, period 2,
ciprofloxacin group) with patients who did not receive
any antibiotic prophylaxis (2005, period 1, control group).
Patients could be included more than once provided
that more than 30 days had elapsed between two episodes
of neutropenia. The groups were compared regarding
demographic characteristics (age, gender), underlying
disease, type of treatment (induction or intensification
for acute leukemia), type of HCT (autologous or allogen-
eic), Karnofsky’s performance status, presence and severity
of mucositis (Common Toxicity Criteria of National Can-
cer Institute World Health Organization criteria), and dur-
ation of neutropenia. We analyzed the following clinical
outcomes: occurrence of fever, duration of empirical anti-
biotic therapy, bacteremia, bacteremia due to ciprofloxa-
cin-resistant organism, bacteremia due to ESBL-producing
enterobacteria, duration of hospitalization and antimic-
robial therapy, use of carbapenem and glycopeptide,
and death during the episode of neutropenia. All data
were collected prospectively, as part of a large database
of febrile neutropenia.
Neutropenia was defined as an absolute neutrophil
count (ANC) < 500/mm3, and severe neutropenia as an
ANC <100/mm3. Bone marrow recovery was defined as
at least two consecutive ANCs >500/mm3, obtained on
two separate days. Fever was defined as an axillary
temperature >38°C. The febrile episodes were classified
as fever of unknown origin (FUO), bacteremia, micro-
biologically documented infection without bacteremia, or
clinically documented infection, as previously defined [17].
Polymicrobial bacteremia was defined if more than
one pathogen was isolated from one or more blood cul-
tures taken on the same day during the febrile episode.
Blood cultures were processed with the BacT/ALERT
system (Organon Teknika, USA). Bacterial identification
and antimicrobial susceptibility tests were performed
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using the Vitek automated system (Bio-Merieux, Inc.,
France). No changes in microbiological procedures took
place during the study period (2005-2008).
All bloodstream isolates from this cohort that had been
stored (-80°C) were reprocessed to evaluate susceptibility.
The following tests were performed: antimicrobial sus-
ceptibility test by disk-diffusion [18], minimal inhibitory
concentration (MIC) of ciprofloxacin by E-test (Probac
do Brasil), and determination of ESBL production by
enterobacteria, with a double-diffusion test (using cefta-
zidime, cefepime, cefotaxime and aztreonam containing
disks as substrates, and amoxicillin-clavulanate containing
disks as inhibitor) [19]. If the isolate was not available for
these additional procedures, data were obtained from the
records of the microbiology laboratory.
In order to rule out the possibility that horizontal
transmission of isolates occurred during the study
period, molecular typing of Gram-negative isolates was
performed using polymerase chain reaction (PCR)-fin-
gerprinting with the following primers: ERIC-2 for
Escherichia coli, Klebsiella spp., Enterobacter spp., and
Citrobacter freundii [20,21], and 272 for Serratia
marcescens and Proteus mirabilis isolates [22]. Banding
patterns were interpreted by visual inspection and with
GelCompar II (version 4.01), using the Dice index and
the unweighted pair group method with arithmetic av-
erages (UPGMA).
In addition to the analysis of resistance among patients
in the cohort, we looked at the rates of resistance of
bloodstream isolates obtained from patients of the unit
who were not in the cohort, as well as the rates in other
units of the hospital in the same 4-year period. Patients
not in the cohort comprised 11,975 patients-day and
included both neutropenic and non-neutropenic patients.
We looked specifically at the rates of ciprofloxacin resist-
ance and ESBL production. Resistance rates were reported
per 1,000 patients.day.
All statistical analyses were performed using the SPSS
for Windows software (version 11.0.1, SPSS, Inc., USA).
The Chi-square test was used to compare proportions,
and Mann–Whitney test to compare continuous variables;
p values <0.05 were considered statistically significant.
Results
We analyzed 220 patients (141 in the ciprofloxacin and
79 in the control group) who developed 329 episodes of
neutropenia, 219 receiving ciprofloxacin prophylaxis (cip-
rofloxacin group) and 110 without quinolone prophylaxis
(control group). Patients in the ciprofloxacin and control
group had similar ages (mean 40 years, range 14 – 82
and 41 years, range 12 – 66, respectively, p=0.56) and
gender (60% and 65% of males, respectively, p = 0.28).
Ciprofloxacin prophylaxis was given for a mean of 11
days (range 1 – 30, SD ± 4.44), and was started before
neutropenia in 94% of episodes, at a mean of 7 days be-
fore neutropenia (8 – 23, SD ± 3.49).
Table 1 shows the characteristics and outcomes of the
episodes of neutropenia in the two groups. The duration
of neutropenia was slightly shorter in the ciprofloxacin
group (9 vs. 11 days, p = 0.02). In addition, mucositis (at
any grade, but not grades 3 or 4) was less frequent in
ciprofloxacin recipients (52% vs. 70%, p = 0.003). Febrile
episodes were significantly less frequent in the cipro-
floxacin group (73 vs. 93%, p < 0.001), and when present,
occurred later in the course of neutropenia (median 4
vs. 2 days after the first day of neutropenia, p < 0.001).
While the proportion of episodes classified as FUO and
clinically documented infection was similar in the two
groups, bacteremia was significantly less frequent in the
ciprofloxacin group (22% vs. 33%, p = 0.04). In addition,
the mean duration of hospitalization was shorter in the
ciprofloxacin group (22 vs. 24 days, p = 0.002), as was
the mean duration of antibiotic therapy (8 vs. 11 days,
p < 0.001) (Additional file 1).
The rates of clinical or microbiological failure to the
empirical treatment with cefepime were similar in the
ciprofloxacin and control groups (12% vs. 8% for clinical
failures, p = 0.33; and 8.5% and 6% for microbiological
failures, p = 0.14; respectively). In addition, no differences
were observed in the frequency of glycopeptide use be-
tween the two groups. However, carbapenems were given
more frequently to ciprofloxacin recipients (36% vs. 14%,
p < 0.001).
A total of 98 bacterial isolates were recovered from the
85 episodes of bacteremia. In the ciprofloxacin group,
there were 19 episodes with documentation of a single
Gram-negative, 22 episodes with a single Gram-positive,
and 8 episodes of polymicrobial bacteremia, whereas in
the control group there were 13 episodes with documenta-
tion of a single Gram-negative, 18 episodes of a single
Gram-positive isolate, and 5 episodes of polymicrobial
bacteremia (Table 1). Table 2 shows the species distri-
bution of bloodstream isolates in both groups. The
most frequent Gram-negative bacteria were E. coli and
P. aeruginosa.
Table 3 shows the resistance rates (per 1,000 patients.
day) in the two periods. The rate of quinolone-resistant
bacteremia (both Gram-positive and Gram-negative)
was significantly higher in patients receiving quinolone
prophylaxis (6.77 vs. 3.02 per 1,000 patients.day, p = 0.03).
In addition, quinolone-resistant enterobacteria were more
frequently isolated in period 2 both in cohort patients
and in the hematology unit overall (2.12 vs. 0.38 per 1,000
patients.day, p = 0.06 in cohort patients, and 2.54 vs. 0.53
per 1,000 patients.day in the hematology unit, p = 0.004),
but remained stable in the hospital (0.76 in period 1 and
0.64 in period 2, p = 0.15). The rates of ESBL production
among enterobacteria increased slightly both in cohort
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patients (0.38 in period vs.1.27 in period 2, p = 0.26) and
in the hematology unit (0.52 in period 1 vs. 1.59 in period
2, p = 0.08), and remained stable in the hospital (0.56 in
period 1 vs. 0.53 in period 2, p = 0.74). No changes in
quinolone resistance among staphylococci were observed
in cohort patients.
The genotypic analysis of the isolates from the cohort
patients showed a great genetic diversity among isolates
recovered from episodes of the cohort, with no similarity
between isolates (Figure 1).
Discussion
In this study we observed that ciprofloxacin prophylaxis
in high-risk neutropenic patients was associated with a de-
crease (and delay) in the occurrence of fever, bacteremia,
and duration of antibiotic therapy and hospitalization.
On the other hand, an increase in the frequency of
quinolone resistance was observed, not only in patients
receiving quinolones but in the whole hematology unit.
In addition, the incidence of bacteremia due to ESBL-
producing enterobacteria increased in the hematology
unit, while in the hospital it remained stable.
Quinolones have been used as prophylaxis in neutro-
penic patients since the early 1990s. While its use has
been associated with favorable outcomes, the drawback
of resistance has been always a concern. Nevertheless,
quinolone prophylaxis is considered standard of care in
high risk neutropenic patients admitted to centers in
which quinolone resistance is <30% [23,24].
The beneficial effects of quinolone prophylaxis observed
in the present study were reported in the majority of
Table 1 Characteristics and outcomes of 329 neutropenic
episodes in 220 patients who received or not









Acute myeloid leukemia 48 (22) 22 (20) 0.69
Acute lymphoid leukemia 48 (22) 24 (22) 0.98
Multiple myeloma 56 (26) 31 (28) 0.61
Non-Hodgkin lymphoma 40 (18) 8 (7) 0.008
Hodgkin lymphoma 18 (8) 15 (14) 0.12
Other* 9 (4) 10 (9) -
Autologous HCT 89 (41) 53 (48) 0.19
Allogeneic HCT 30 (14) 14 (13) 0.81
Central venous catheter 140 (64) 73 (66) 0.66
Performance status <50% 25 (11) 19 (17) 0.14
Mucositis, any grade 114 (52) 76 (70) <0.001
Grade 3 or 4 28 (13) 16 (15) 0.66
Duration (days) of neutropenia,
mean ±SD (range)
9 ± 6.3 (2–47) 11 ± 7.9
(2–61)
0.02
Duration (days) of severe
neutropenia, mean ±SD (range)
7 ± 5.2 (1–38) 8 ± 6.9
(0–40)
0.39
Fever 159 (73) 102 (93) <0.001
Fever of unknown origin 86 (39) 52 (47) 0.16
Bacteremia 49 (22) 36 (33) 0.04
due to a single
Gram-negative
19 (9) 13 (12) 0.36
due to a single
Gram-positive
22 (10) 18 (16) 0.10
Polymicrobial 8 (4) 5 (4.5) 0.77
Microbiologically
documented without bacteremia
3 (1) 1 (1) 1.00
Clinically documented 21 (10) 12 (11) 0.71
Duration of hospitalization (days),
mean ±SD (range)






treatment (days) , mean ±SD
(range)
8 ± 7.6 (0 – 40) 11 ± 7.0 (0
– 33)
<0.001
Receipt of carbapenem** 79 (36) 15 (14) <0.001
Receipt of glycopeptide 26 (24) 14 (13) 0.82
Death 20 (9) 12 (11) 0.61
Data are number (%) of episodes, unless otherwise indicated.
* Other underlying diseases: Ciprofloxacin group: aplastic anemia (5 episodes),
and chronic myeloid leukemia and germ cell tumor (1 each); control group:
chronic myeloid leukemia (9), and aplastic anemia (1).
** As empirical therapy in 43 episodes in the ciprofloxacin group and 1 in the
control group; as a modification of the empirical regimen in 14 episodes in
the ciprofloxacin group and in 36 episodes in the control group.
Table 2 Species distribution of 98 bacterial bloodstream
isolates recovered from patients who received
ciprofloxacin prophylaxis or not during neutropenia





Staphylococcus aureus 4 1
α- Hemolytic streptococci 5 4
Other Gram-positive* 5 3
Gram-negative N=29 N=17
Escherichia coli 9 5
Klebsiella pneumoniae 2 1
Other enterobacteria** 4 4




The total number of isolates exceeds the number of bacteremias because
there were 13 episodes of polymicrobial bacteremia.
* Ciprofloxacin group: Enterococcus sp. and Streptococcus pneumoniae (1 each),
and 3 Gram-positive rods; Control group: Enterococcus sp. (2) and Bacillus sp. (1).
** Ciprofloxacin group: Enterobacter sp. (3), and Shigella sp. (1); Control group:
Citrobacter sp. (2), and Enterobacter sp. and Serratia sp. (1 each).
*** Ciprofloxacin group: 5 Acinetobacter sp., 3 Stenotrophomonas maltophilia,
and 3 Burkholderia cepacia; Control group: 1 Acinetobacter sp., 1
Stenotrophomonas maltophilia, and 1 Burkholderia cepacia.
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randomized clinical trials. In one multicenter trial
conducted in Italy, the use of levofloxacin in patients with
expected duration of neutropenia >7 days resulted in a
reduction in episodes of febrile neutropenia and
bacteremia [1]. In another trial, the same benefits were
observed, but there was an increase in the use of
carbapenems [25], as observed in the present study.
While these studies give support to the use of quin-
olone prophylaxis in a select group of neutropenic pa-
tients, some important aspects regarding antimicrobial
resistance have not been addressed. For example, the
Italian trial showed that the rate of levofloxacin-resistant
Gram-negative bloodstream isolates was 4-fold higher in
levofloxacin recipients, but data regarding the frequency
of resistance to other antimicrobial classes, such as beta-
lactams, were not provided [1]. Likewise, other studies
emphasized the emergence of quinolone resistance but
provided few data regarding increasing of resistance to
other antimicrobials [26-28]. The relationship between
quinolone exposure and the emergency of ESBL produc-
tion among enterobacteria is well documented, and is
thought to be a result of the mutant window, a pheno-
menon in which a quinolone-resistant isolate is more
likely to acquire other mechanisms of resistance [9].
The increased use of carbapenem in the second period
of our study was mostly as primary antibiotic regimen for
the first fever (43 episodes in the ciprofloxacin group vs. 1
in the control group). The increased use of carbapenems
in the empirical regimen may have been due to a concern
of clinicians when we started to experience an increase
Figure 1 Molecular analysis of Escherichia coli isolates from cohort patients. A. ERIC2-PCR profiles of Escherichia coli isolates. Lanes 1 and
23: 1 Kb plus molecular size marker; Lanes 2–20: clinical isolates; Lanes 21 and 22: control strains ST69 and ATCC25922. B. Dendrogram of ERIC-2
PCR profiles of Escherichia coli isolates. C: control isolates.









Bacteremia due to Cip-R
organisms*
3.02 6.77 0.03
Cip-R enterobacteria 0.38 2.12 0.06
Cip-R Pseudomonas aeruginosa 0.38 0.63 0.71
ESBL production 0.38 1.27 0.26
Cip-R Staphylococcus aureus 0 0.63 0.26
Cip-R CONS 2.27 2.75 0.72
Non-cohort patients in the hematology unit
Cip-R enterobacteria 0.53 2.54 0.004
Cip-R Pseudomonas aeruginosa 0.70 0.32 0.39
ESBL production 0.52 1.59 0.08
Cip-R Staphylococcus aureus 0 0.16 0.52
Cip-R CONS 2.64 2.23 0.65
Hospital
Cip-R enterobacteria 0.76 0.64 0.15
Cip-R Pseudomonas aeruginosa 0.22 0.21 0.78
ESBL production 0.56 0.53 0.74
Cip-R Staphylococcus aureus 0.33 0.23 0.06
Cip-R CONS 0.68 0.60 0.33
Cip-R = ciprofloxacin-resistant; ESBL = extended spectrum beta-lactamase;
CONS = coagulase-negative staphylococci; *Total number of bacteremia due
to quinolone-resistant organisms available in the cohort only.
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in the rate of bacteremia due to ESBL-producing entero-
bacteria. Although not significant, there was a slight in-
crease in the recovery of ESBL-producing enterobacteria
in period 2 both in the cohort group and in the he-
matology unit. However, a similar trend was not observed
in the hospital in the same period. These data indicate
that the increase in ESBL in the hematology unit was
not a reflection of an increase in ESBL in the hospital,
and suggest a relationship between quinolone use and
ESBL. In support of this hypothesis are various studies
reporting a close association between quinolone resist-
ance and ESBL [9,29]. Furthermore, the lack of genetic
similarity among the bloodstream isolates suggests that
horizontal transmission was not the main factor res-
ponsible for the increase in the incidence of quinolone-
resistant and ESBL-producing enterobacteria. Therefore,
a careful judgment of the risks and benefits of quin-
olone resistance should be advanced.
Our study is limited by the fact that we used a historical
control group. However, except for time (two different
periods) and antibacterial prophylaxis policy (ciprofloxacin
or not), no other intervention was carried out that could
strongly influence the results. Specifically, no changes
in antimicrobial use in the unit or in microbiological
procedures occurred in the two periods. Another limi-
tation of our study is that not all bacteria recovered
from blood cultures in the period were available for
further laboratory analysis.
Conclusion
In conclusion, ciprofloxacin prophylaxis was beneficial in
high risk neutropenic patients, but important modifi-
cations in the prescription of carbapenems and on anti-
microbial resistance patterns of isolates were observed.
The importance of hospital or ward ecology must be taken
into account when deciding for quinolone prophylaxis in
high-risk neutropenic patients.
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